CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy)

CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy)

Introduction

Carasil (Cerebral Autosomal Recessive Arteriopathy With Subcortical Infarcts And Leukoencephalopathy) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@mancuso2020]

Overview

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a rare hereditary [cerebral small vessel disease/diseases) caused by homozygous or compound heterozygous loss-of-function mutations in the HTRA1 gene. CARASIL is characterized by a clinical triad of early-onset ischemic strokes, progressive cognitive decline leading to dementia, and distinctive systemic features including premature alopecia (baldness) and degenerative lumbar disc disease (spondylosis deformans) . [@mancuso2020] [@ashrafi2020]

First described by Maeda et al. in 1976 in Japan, CARASIL was originally termed "familial Binswanger disease with alopecia" before receiving its current designation. The identification of HTRA1 mutations as the genetic cause by Hara et al. in 2009 represented a landmark discovery linking TGF dysregulation to [cerebral small vessel disease/diseases) . [@ashrafi2020] [@ferrer2017]

CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy)

Introduction

Carasil (Cerebral Autosomal Recessive Arteriopathy With Subcortical Infarcts And Leukoencephalopathy) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@mancuso2020]

Overview

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a rare hereditary [cerebral small vessel disease/diseases) caused by homozygous or compound heterozygous loss-of-function mutations in the HTRA1 gene. CARASIL is characterized by a clinical triad of early-onset ischemic strokes, progressive cognitive decline leading to dementia, and distinctive systemic features including premature alopecia (baldness) and degenerative lumbar disc disease (spondylosis deformans) . [@mancuso2020] [@ashrafi2020]

First described by Maeda et al. in 1976 in Japan, CARASIL was originally termed "familial Binswanger disease with alopecia" before receiving its current designation. The identification of HTRA1 mutations as the genetic cause by Hara et al. in 2009 represented a landmark discovery linking TGF dysregulation to [cerebral small vessel disease/diseases) . [@ashrafi2020] [@ferrer2017]

CARASIL is the autosomal recessive counterpart to [CADASIL/diseases), the more common autosomal dominant form of hereditary cerebral small vessel disease caused by NOTCH3 mutations. While both diseases share features of subcortical ischemic stroke and white matter degeneration, they differ in their genetic basis, systemic manifestations, and underlying vascular pathology . [@tikka2014]

Epidemiology

CARASIL is an extremely rare condition : [@chojdakukasiewicz2021]

• Approximately 50-70 cases have been reported in the medical literature worldwide
• Geographic distribution: The majority of confirmed cases have been reported in Japan and China, though cases have also been identified in Turkey, Pakistan, Portugal, Spain, Romania, India, and other countries
• Prevalence: Unknown, but estimated to be substantially rarer than](/diseases/cadasil) (which has an estimated prevalence of 2-5 per 100,000)
• The disease likely remains significantly underdiagnosed, particularly outside of Japan where clinical awareness is lower
• Consanguinity is present in many affected families, consistent with autosomal recessive inheritance
• Males and females are affected equally

Genetics

HTRA1 Gene

The HTRA1 gene, located on chromosome 10q26.13, encodes a member of the high-temperature requirement A family of serine proteases. HTRA1 is a 51 kDa secreted protein with multiple functional domains : [@diwan2012]

• Signal peptide: Targets the protein for secretion
• IGFBP domain: Insulin-like growth factor binding protein domain
• Kazal-type serine protease inhibitor domain: Regulatory function
• Serine protease domain: Catalytic trypsin-like domain responsible for proteolytic activity
• PDZ domain: Mediates protein-protein interactions and oligomerization

Mutation Spectrum

Pathogenic mutations in HTRA1 causing CARASIL include: [@uemura2020]

• Missense mutations in the protease domain: The most common type, disrupting catalytic activity or substrate binding
• Nonsense mutations: Creating premature stop codons
• Frameshift mutations: Resulting in truncated, non-functional protein
• Splice-site mutations: Disrupting mRNA processing
• Some mutations are hypomorphic (partial loss of function) while others cause complete loss of protease activity

HTRA1-Related Heterozygous Disease

Importantly, heterozygous HTRA1 mutations have been increasingly recognized as a cause of autosomal dominant cerebral small vessel disease, sometimes termed "CARASIL2" or "HTRA1-related cerebral small vessel disease." These heterozygous carriers may develop a milder phenotype with later onset, reduced penetrance, and variable systemic features . This dominant-negative mechanism may account for a substantial proportion of previously unexplained familial cerebral small vessel disease. [@fang2023]

Genotype-Phenotype Correlations

• Complete loss-of-function mutations (homozygous null): Classic CARASIL with early onset and full triad
• Partial loss-of-function mutations (hypomorphic): May present with later onset or incomplete clinical features
• Heterozygous carriers: Historically considered asymptomatic, but now recognized to develop cerebral small vessel disease in some cases, typically with later onset (50s-60s) and without alopecia or spondylosis

Pathophysiology

HTRA1 and TGF-beta Signaling

HTRA1 functions as a negative regulator of TGF-beta (transforming growth factor-beta) signaling. Under normal conditions, HTRA1 cleaves and inactivates TGF-beta family members and their downstream mediators, maintaining vascular homeostasis :

• Substrate cleavage: HTRA1 degrades TGF-beta propeptides (latency-associated peptide), mature TGF-beta ligands, and downstream effectors
• Extracellular matrix regulation: HTRA1 cleaves fibronectin, vitronectin, decorin, fibromodulin, and other extracellular matrix (ECM) proteins, maintaining normal matrix turnover
• Matrisome regulation: HTRA1 processes proteins involved in blood vessel wall integrity and remodeling

Consequences of HTRA1 Loss

Loss of HTRA1 protease activity leads to :

Vascular Pathology

CARASIL is characterized by non-amyloid, non-atherosclerotic arteriosclerosis of small penetrating cerebral arteries :

• Concentric hyalinosis: Thickened, hyalinized vessel walls
• Loss of smooth muscle cells: Progressive replacement of medial smooth muscle with fibrous tissue
• Elastic lamina changes: Multilamination, splitting, and fragmentation of the internal elastic lamina
• Absence of granular osmiophilic material (GOM): Distinguishes CARASIL from [CADASIL/diseases), where GOM deposits in vessel walls are pathognomonic
• Absence of amyloid: Distinguishes CARASIL from](/cerebral-amyloid-angiopathy-))

Systemic Manifestations

• Alopecia: Premature hair loss beginning in adolescence, caused by dysregulated TGF in hair follicle stem cells, affecting the hair growth cycle
• Spondylosis deformans: Degenerative disc disease and vertebral body changes resulting from abnormal ECM remodeling in intervertebral discs, driven by excessive TGF

Clinical Presentation

Cardinal Features

CARASIL presents with a characteristic clinical triad :

1. Cerebrovascular Disease

• Ischemic strokes: Lacunar infarcts in deep white matter, basal ganglia, thalamus, and pons
• Onset: First strokes typically in the late twenties to thirties
• Recurrent episodes: Progressive accumulation of ischemic lesions
• Gait disturbance: Spasticity, particularly in the lower extremities, often an early sign
• No association with traditional vascular risk factors: Hypertension, diabetes, and hyperlipidemia are typically absent

2. Progressive Cognitive Decline

• Onset: Gradual cognitive deterioration beginning in the thirties
• Pattern: Subcortical [Vascular Dementia/diseases) with prominent executive dysfunction, psychomotor slowing, and personality/mood changes
• Progression: Steadily progressive, leading to severe dementia by the forties to fifties
• Memory: Retrieval-type memory deficits (benefiting from cueing), unlike the storage deficits of](/diseases/alzheimers-disease)

3. Systemic Features

• Alopecia: Premature hair loss, typically beginning in adolescence (teens to early twenties). Present in approximately 80-90% of cases
• Spondylosis deformans / lumbar disc disease: Low back pain beginning in the twenties, sometimes the earliest symptom. Present in approximately 70-80% of cases

Features That Distinguish CARASIL from CADASIL

| Feature | CARASIL | [CADASIL/diseases) |
|---------|---------|--------|
| Inheritance | Autosomal recessive (HTRA1) | Autosomal dominant (NOTCH3) |
| Gene | HTRA1 (10q26.13) | NOTCH3 (19p13.12) |
| Prevalence | ~50-70 cases reported | 2-5 per 100,000 |
| Stroke onset | Late twenties to thirties | Forties to fifties |
| Migraine with aura | Typically absent | Present in ~40% |
| Alopecia | Present (~80-90%) | Absent |
| Spondylosis | Present (~70-80%) | Absent |
| Hypertension | Absent | Absent |
| GOM deposits | Absent | Present (pathognomonic) |
| Temporal pole involvement | Less prominent | Characteristic on MRI |

Atypical Presentations

• Some cases lack alopecia, making clinical distinction more challenging
• Isolated cerebrovascular disease without systemic features may occur with hypomorphic mutations
• CARASIL may mimic](/diseases/multiple-sclerosis) when white matter lesions are prominent

Neuroimaging

MRI Findings

Brain MRI in CARASIL shows findings typical of [cerebral small vessel disease/diseases):

• T2/FLAIR hyperintensities: Confluent white matter lesions in periventricular and deep white matter, often symmetric and extensive
• Lacunar infarcts: Multiple small infarcts in the basal ganglia, thalamus, internal capsule, pons, and deep white matter
• Cerebral microbleeds: May be present on susceptibility-weighted imaging (SWI)
• Brain atrophy: Progressive generalized atrophy, particularly of deep gray matter structures
• Dilated perivascular spaces: Enlarged Virchow-Robin spaces

Differences from CADASIL on MRI

• ](/diseases/cadasil) characteristically involves the anterior temporal poles and external capsules -- findings that are less prominent in CARASIL
• CARASIL tends to show more homogeneously distributed white matter changes without the temporal pole predilection

Spinal Imaging

• Degenerative disc disease with disc space narrowing
• Vertebral body deformities
• Often more severe than expected for the patient's age

Diagnosis

Diagnostic Approach

Differential Diagnosis

• [CADASIL/diseases) -- dominant inheritance, migraines, temporal pole involvement, GOM deposits

• [Cerebral amyloid angiopathy/diseases) -- lobar hemorrhages, amyloid on biopsy

• [Cerebral small vessel disease/diseases) (sporadic) -- typically later onset with hypertension

Treatment and Management

Current Treatment

There is no disease-modifying therapy for CARASIL. Management is supportive and symptomatic :

• Stroke prevention: Antiplatelet agents (aspirin, clopidogrel) for secondary stroke prevention
• Vascular risk factor management: Control of any modifiable risk factors
• Cognitive support: Cognitive rehabilitation, occupational therapy, psychosocial support
• Spasticity management: Physical therapy, antispasticity medications (baclofen, tizanidine)
• Pain management: Treatment of back pain from spondylosis
• Mood management: Antidepressants for associated mood disorders
• Genetic counseling: Essential for families; carrier testing available for at-risk relatives

Emerging Therapeutic Strategies

Recent research (2024) has explored molecular strategies to restore HTRA1 function :

These approaches are still in preclinical stages but represent the first disease-modifying strategies under development for CARASIL.

TGF-beta Pathway Modulation

Since excessive TGF drives CARASIL pathology, therapeutic targeting of this pathway is of interest:

• Losartan and other angiotensin receptor blockers can reduce TGF and have shown benefit in other TGF-beta-driven conditions (e.g., Marfan syndrome)
• Careful balance is needed, as TGF-beta plays important physiological roles in vascular homeostasis and immune regulation

Prognosis

• Disease course: Progressive and relentless; gradual accumulation of ischemic lesions and cognitive decline
• Functional disability: Most patients become wheelchair-bound and require full-time care by the forties to fifties
• Life expectancy: Reduced, though specific survival data are limited due to disease rarity. Death typically occurs in the fifties to sixties
• Cognitive prognosis: Inevitable progression to severe dementia

Current Research

Animal Models

• Htra1 knockout mice show vascular changes resembling CARASIL, including smooth muscle cell loss and ECM accumulation in cerebral small vessels
• These models are being used to test TGF interventions and gene therapy approaches

Genetic Epidemiology

• Heterozygous HTRA1 mutations are increasingly recognized as a significant cause of apparently sporadic cerebral small vessel disease
• Population-based studies are assessing the prevalence of heterozygous HTRA1 variants among patients with unexplained white matter disease

Biomarker Development

• Plasma matrisome components are being explored as potential [biomarkers](/biomarkers) for CARASIL and heterozygous HTRA1 disease
• Identification of blood-based biomarkers could aid early diagnosis and therapeutic monitoring

Gene Therapy

• AAV-mediated delivery of functional HTRA1 gene to vascular smooth muscle cells and the CNS is under preclinical investigation

See Also

• [All Diseases

Background

The study of Carasil (Cerebral Autosomal Recessive Arteriopathy With Subcortical Infarcts And Leukoencephalopathy) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

Recent advances in CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:

• Genetic studies: Identification of new genetic risk factors and mechanistic insights
• Biomarker research: Development of diagnostic and prognostic biomarkers
• Therapeutic approaches: Investigation of novel treatment strategies
• Clinical trials: Ongoing Phase I-III trials for new therapies

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References